SIGA Technologies, Inc. (SIGA)
USD 5.63
(3.68%)
USD 5.63
(3.68%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 57.97 Million USD | 133.07% |
| 2022 | 24.87 Million USD | -38.44% |
| 2021 | 40.41 Million USD | 101.68% |
| 2020 | 20.03 Million USD | -80.12% |
| 2019 | 100.78 Million USD | 0.25% |
| 2018 | 100.52 Million USD | -78.51% |
| 2017 | 467.8 Million USD | 4.33% |
| 2016 | 448.4 Million USD | -4.63% |
| 2015 | 470.16 Million USD | 13.87% |
| 2014 | 412.88 Million USD | 133.47% |
| 2013 | 176.84 Million USD | 130.0% |
| 2012 | 76.88 Million USD | 57.9% |
| 2011 | 48.69 Million USD | 225.43% |
| 2010 | 14.96 Million USD | -3.01% |
| 2009 | 15.42 Million USD | 113.0% |
| 2008 | 7.24 Million USD | 35.11% |
| 2007 | 5.36 Million USD | -20.54% |
| 2006 | 6.74 Million USD | 134.72% |
| 2005 | 2.87 Million USD | 85.26% |
| 2004 | 1.55 Million USD | 182.97% |
| 2003 | 548.23 Thousand USD | -16.54% |
| 2002 | 656.9 Thousand USD | -1.4% |
| 2001 | 666.2 Thousand USD | -70.85% |
| 2000 | 2.28 Million USD | 90.45% |
| 1999 | 1.2 Million USD | -20.0% |
| 1998 | 1.5 Million USD | 200.0% |
| 1997 | 500 Thousand USD | 150.0% |
| 1996 | 200 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 78.15 Million USD | 34.8% |
| 2024 Q2 | 25.1 Million USD | -67.88% |
| 2023 FY | 57.97 Million USD | 133.07% |
| 2023 Q1 | 21.83 Million USD | -12.24% |
| 2023 Q2 | 22.43 Million USD | 2.78% |
| 2023 Q3 | 34.24 Million USD | 52.61% |
| 2023 Q4 | 57.97 Million USD | 69.33% |
| 2022 Q1 | 16.8 Million USD | -58.4% |
| 2022 Q2 | 20.17 Million USD | 20.0% |
| 2022 Q3 | 31.08 Million USD | 54.11% |
| 2022 Q4 | 24.87 Million USD | -19.98% |
| 2022 FY | 24.87 Million USD | -38.44% |
| 2021 Q4 | 40.41 Million USD | 39.32% |
| 2021 FY | 40.41 Million USD | 101.68% |
| 2021 Q3 | 29 Million USD | 70.98% |
| 2021 Q1 | 16.08 Million USD | -19.74% |
| 2021 Q2 | 16.96 Million USD | 5.49% |
| 2020 Q2 | 26.28 Million USD | -13.63% |
| 2020 Q4 | 20.03 Million USD | -29.6% |
| 2020 Q3 | 28.46 Million USD | 8.29% |
| 2020 FY | 20.03 Million USD | -80.12% |
| 2020 Q1 | 30.43 Million USD | -69.8% |
| 2019 Q1 | 100.36 Million USD | -0.16% |
| 2019 Q3 | 100.14 Million USD | 0.51% |
| 2019 Q2 | 99.63 Million USD | -0.73% |
| 2019 FY | 100.78 Million USD | 0.25% |
| 2019 Q4 | 100.78 Million USD | 0.64% |
| 2018 Q2 | 469.65 Million USD | 0.41% |
| 2018 Q4 | 100.52 Million USD | 10.16% |
| 2018 Q1 | 467.75 Million USD | -0.01% |
| 2018 FY | 100.52 Million USD | -78.51% |
| 2018 Q3 | 91.25 Million USD | -80.57% |
| 2017 Q3 | 461.55 Million USD | 0.46% |
| 2017 FY | 467.8 Million USD | 4.33% |
| 2017 Q1 | 456.95 Million USD | 1.91% |
| 2017 Q2 | 459.44 Million USD | 0.54% |
| 2017 Q4 | 467.8 Million USD | 1.36% |
| 2016 Q1 | 479.47 Million USD | 1.98% |
| 2016 Q4 | 448.4 Million USD | -5.8% |
| 2016 Q3 | 476 Million USD | -5.88% |
| 2016 Q2 | 505.74 Million USD | 5.48% |
| 2016 FY | 448.4 Million USD | -4.63% |
| 2015 Q2 | 441.85 Million USD | 3.61% |
| 2015 Q4 | 470.16 Million USD | 1.8% |
| 2015 Q3 | 461.83 Million USD | 4.52% |
| 2015 FY | 470.16 Million USD | 13.87% |
| 2015 Q1 | 426.43 Million USD | 3.28% |
| 2014 FY | 412.88 Million USD | 133.47% |
| 2014 Q4 | 412.88 Million USD | 5.14% |
| 2014 Q3 | 392.69 Million USD | 98.43% |
| 2014 Q2 | 197.9 Million USD | -1.47% |
| 2014 Q1 | 200.85 Million USD | 13.57% |
| 2013 Q1 | 103.22 Million USD | 34.25% |
| 2013 FY | 176.84 Million USD | 130.0% |
| 2013 Q4 | 176.84 Million USD | -2.96% |
| 2013 Q3 | 182.24 Million USD | 18.64% |
| 2013 Q2 | 153.6 Million USD | 48.81% |
| 2012 Q1 | 51.07 Million USD | 4.89% |
| 2012 Q3 | 60.31 Million USD | 3.28% |
| 2012 Q4 | 76.88 Million USD | 27.48% |
| 2012 Q2 | 58.39 Million USD | 14.33% |
| 2012 FY | 76.88 Million USD | 57.9% |
| 2011 Q3 | 4.8 Million USD | -46.74% |
| 2011 Q1 | 11.26 Million USD | -24.71% |
| 2011 FY | 48.69 Million USD | 225.43% |
| 2011 Q4 | 48.69 Million USD | 913.53% |
| 2011 Q2 | 9.01 Million USD | -19.93% |
| 2010 Q1 | 16.27 Million USD | 5.51% |
| 2010 Q3 | 15.94 Million USD | -13.02% |
| 2010 Q4 | 14.96 Million USD | -6.15% |
| 2010 FY | 14.96 Million USD | -3.01% |
| 2010 Q2 | 18.32 Million USD | 12.61% |
| 2009 FY | 15.42 Million USD | 113.0% |
| 2009 Q4 | 15.42 Million USD | -21.53% |
| 2009 Q3 | 19.65 Million USD | -8.24% |
| 2009 Q2 | 21.42 Million USD | 55.63% |
| 2009 Q1 | 13.76 Million USD | 90.09% |
| 2008 Q4 | 7.24 Million USD | -3.61% |
| 2008 FY | 7.24 Million USD | 35.11% |
| 2008 Q1 | 3.7 Million USD | -30.9% |
| 2008 Q2 | 4.97 Million USD | 34.31% |
| 2008 Q3 | 7.51 Million USD | 51.04% |
| 2007 FY | 5.36 Million USD | -20.54% |
| 2007 Q4 | 5.36 Million USD | -15.93% |
| 2007 Q3 | 6.37 Million USD | 18.8% |
| 2007 Q2 | 5.36 Million USD | -34.13% |
| 2007 Q1 | 8.14 Million USD | 20.79% |
| 2006 Q2 | 7.31 Million USD | 30.51% |
| 2006 FY | 6.74 Million USD | 134.72% |
| 2006 Q4 | 6.74 Million USD | 19.36% |
| 2006 Q3 | 5.65 Million USD | -22.79% |
| 2006 Q1 | 5.6 Million USD | 95.16% |
| 2005 Q4 | 2.87 Million USD | 66.51% |
| 2005 FY | 2.87 Million USD | 85.26% |
| 2005 Q2 | 2.67 Million USD | 63.46% |
| 2005 Q3 | 1.72 Million USD | -35.59% |
| 2005 Q1 | 1.63 Million USD | 5.67% |
| 2004 Q2 | 860.61 Thousand USD | 2.29% |
| 2004 Q4 | 1.55 Million USD | 72.75% |
| 2004 Q3 | 898 Thousand USD | 4.34% |
| 2004 Q1 | 841.35 Thousand USD | 53.47% |
| 2004 FY | 1.55 Million USD | 182.97% |
| 2003 FY | 548.23 Thousand USD | -16.54% |
| 2003 Q2 | 917.25 Thousand USD | 72.34% |
| 2003 Q3 | 1.21 Million USD | 32.77% |
| 2003 Q4 | 548.23 Thousand USD | -54.98% |
| 2003 Q1 | 532.22 Thousand USD | -18.98% |
| 2002 Q1 | 572.73 Thousand USD | -14.03% |
| 2002 Q4 | 656.9 Thousand USD | 21.46% |
| 2002 Q3 | 540.85 Thousand USD | -37.45% |
| 2002 Q2 | 864.67 Thousand USD | 50.97% |
| 2002 FY | 656.9 Thousand USD | -1.4% |
| 2001 Q2 | 991.19 Thousand USD | -58.84% |
| 2001 Q3 | 1.08 Million USD | 9.54% |
| 2001 Q1 | 2.4 Million USD | 5.37% |
| 2001 FY | 666.2 Thousand USD | -70.85% |
| 2001 Q4 | 666.2 Thousand USD | -38.64% |
| 2000 FY | 2.28 Million USD | 90.45% |
| 2000 Q3 | 1.95 Million USD | 15.23% |
| 2000 Q4 | 2.28 Million USD | 16.8% |
| 2000 Q1 | 1.41 Million USD | 18.03% |
| 2000 Q2 | 1.69 Million USD | 19.89% |
| 1999 Q3 | 1.2 Million USD | 0.0% |
| 1999 Q2 | 1.2 Million USD | -7.69% |
| 1999 Q1 | 1.3 Million USD | -13.33% |
| 1999 FY | 1.2 Million USD | -20.0% |
| 1999 Q4 | 1.2 Million USD | 0.0% |
| 1998 FY | 1.5 Million USD | 200.0% |
| 1998 Q2 | 500 Thousand USD | 66.67% |
| 1998 Q3 | 1.6 Million USD | 220.0% |
| 1998 Q4 | 1.5 Million USD | -6.25% |
| 1998 Q1 | 300 Thousand USD | -40.0% |
| 1997 FY | 500 Thousand USD | 150.0% |
| 1997 Q4 | 500 Thousand USD | 150.0% |
| 1997 Q3 | 200 Thousand USD | 0.0% |
| 1996 FY | 200 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 87.708% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 64.628% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 93.883% |
| Cosmos Health Inc. | 30.25 Million USD | -91.644% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -582.846% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 91.226% |
| Cronos Group Inc. | 43.73 Million USD | -32.562% |
| Incannex Healthcare Limited | 5.83 Million USD | -894.465% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -19.677% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 73.623% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -26311.898% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -844.317% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -844.317% |
| SCYNEXIS, Inc. | 55.45 Million USD | -4.558% |
| Safety Shot Inc | 3.89 Million USD | -1389.636% |
| Theratechnologies Inc. | 98.63 Million USD | 41.223% |
| Alpha Teknova, Inc. | 38.55 Million USD | -50.391% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -321.52% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 91.768% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -562.144% |
| Dynavax Technologies Corporation | 375.02 Million USD | 84.54% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 92.907% |
| Radius Health, Inc. | 804.29 Million USD | 92.791% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -530.42% |
| Alvotech | 1.88 Billion USD | 96.92% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 57.641% |
| Shineco, Inc. | 47.6 Million USD | -21.797% |
| Silver Spike Investment Corp. | 3 Million USD | -1826.264% |
| Journey Medical Corporation | 56.49 Million USD | -2.616% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -171.992% |
| Embecta Corp. | 2.03 Billion USD | 97.153% |
| Harrow Health, Inc. | 241.75 Million USD | 76.018% |
| Procaps Group, S.A. | 462.06 Million USD | 87.453% |
| Biofrontera Inc. | 23.13 Million USD | -150.561% |
| DURECT Corporation | 30.4 Million USD | -90.677% |
| PainReform Ltd. | 2.69 Million USD | -2054.489% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 88.106% |
| OptiNose, Inc. | 194.33 Million USD | 70.166% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -176.37% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 68.032% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -10.399% |
| ProPhase Labs, Inc. | 42.54 Million USD | -36.276% |
| Phibro Animal Health Corporation | 725.54 Million USD | 92.009% |
| Procaps Group S.A. | 462.06 Million USD | 87.453% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -313.474% |
| Viatris Inc. | 27.21 Billion USD | 99.787% |
| Rockwell Medical, Inc. | 30.88 Million USD | -87.738% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 35.851% |
| Tilray Brands, Inc. | 892.11 Million USD | 93.501% |
| PetIQ, Inc. | 645.22 Million USD | 91.014% |
| Talphera, Inc. | 6.29 Million USD | -821.737% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 94.313% |
| Alimera Sciences, Inc. | 107.35 Million USD | 45.994% |
| Assertio Holdings, Inc. | 148.41 Million USD | 60.936% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -2957.93% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 66.562% |
| Hempacco Co., Inc. | 18.82 Million USD | -208.023% |
| Alvotech | 1.88 Billion USD | 96.92% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 93.059% |
| Kamada Ltd. | 109.96 Million USD | 47.278% |
| Currenc Group, Inc. | 177.67 Million USD | 67.369% |
| Indivior PLC | 1.95 Billion USD | 97.029% |
| Evoke Pharma, Inc. | 9.64 Million USD | -500.92% |
| Flora Growth Corp. | 17.22 Million USD | -236.647% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -582.846% |
| Evolus, Inc. | 209.68 Million USD | 72.351% |
| HUTCHMED (China) Limited | 536.38 Million USD | 89.191% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 93.363% |
| Akanda Corp. | 12.66 Million USD | -357.635% |